{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:50:11Z","timestamp":1774867811114,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.bbr.2008.06.035","type":"journal-article","created":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T04:02:23Z","timestamp":1215403343000},"page":"152-161","source":"Crossref","is-referenced-by-count":27,"title":["A novel adenosine A1 and A2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs"],"prefix":"10.1016","volume":"194","author":[{"given":"Takuma","family":"Mihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuya","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2008.06.035_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","article-title":"Adenosine A(2A) receptor antagonist treatment of Parkinson's disease","volume":"61","author":"Bara-Jimenez","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2008.06.035_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/brcg.1999.1083","article-title":"Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome","volume":"40","author":"Bedard","year":"1999","journal-title":"Brain Cognit"},{"key":"10.1016\/j.bbr.2008.06.035_bib3","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2008.06.035_bib4","doi-asserted-by":"crossref","first-page":"161S","DOI":"10.1592\/phco.27.12part2.161S","article-title":"Pharmacotherapy for Parkinson's disease","volume":"27","author":"Chen","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbr.2008.06.035_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02244093","article-title":"Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease","volume":"102","author":"Close","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2008.06.035_bib6","doi-asserted-by":"crossref","unstructured":"Crosby N, Deane KH, Clarke CE, Amantadine in Parkinson's disease, Cochrane database of systematic reviews (Online), 2003; CD003468.","DOI":"10.1002\/14651858.CD003468"},{"key":"10.1016\/j.bbr.2008.06.035_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0149-7634(96)00037-1","article-title":"Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents\u2013preclinical studies","volume":"21","author":"Danysz","year":"1997","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.bbr.2008.06.035_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-1781(79)90006-4","article-title":"Chronic Parkinsonism secondary to intravenous injection of meperidine analogues","volume":"1","author":"Davis","year":"1979","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.bbr.2008.06.035_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease","volume":"41","author":"Deleu","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bbr.2008.06.035_bib10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1006\/exnr.1998.6859","article-title":"Trihexyphenidyl potentiation of l-DOPA: reduced effectiveness three years later in MPTP-induced chronic hemiparkinsonian monkeys","volume":"152","author":"Domino","year":"1998","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2008.06.035_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ana.410280202","article-title":"Cholinergic deficiency and frontal dysfunction in Parkinson's disease","volume":"28","author":"Dubois","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2008.06.035_bib12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0166-2236(97)01096-5","article-title":"Adenosine\u2013dopamine receptor\u2013receptor interactions as an integrative mechanism in the basal ganglia","volume":"20","author":"Ferre","year":"1997","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bbr.2008.06.035_bib13","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1073\/pnas.88.16.7238","article-title":"Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes","volume":"88","author":"Ferre","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbr.2008.06.035_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0169-328X(92)90173-9","article-title":"Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum","volume":"14","author":"Fink","year":"1992","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.bbr.2008.06.035_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejphar.2005.06.035","article-title":"Interactions between adenosine A(2a) and dopamine D2 receptors in the control of [(3)H]GABA release in the globus pallidus of the rat","volume":"520","author":"Floran","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2008.06.035_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0091-3057(00)00305-1","article-title":"Effects of ropinirole on motor behavior in MPTP-treated common marmosets","volume":"67","author":"Fukuzaki","year":"2000","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bbr.2008.06.035_bib17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1046\/j.0953-816x.2001.01759.x","article-title":"Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats","volume":"14","author":"Hauber","year":"2001","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bbr.2008.06.035_bib18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.104.066191","article-title":"Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"310","author":"Hill","year":"2004","journal-title":"Journal Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2008.06.035_bib19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00023210-200721080-00005","article-title":"Medical management of levodopa-associated motor complications in patients with Parkinson's disease","volume":"21","author":"Jankovic","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2008.06.035_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0014-2999(89)90571-2","article-title":"Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680","volume":"168","author":"Jarvis","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2008.06.035_bib21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","article-title":"Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys","volume":"43","author":"Kanda","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2008.06.035_bib22","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1271\/bbb.65.1447","article-title":"New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia","volume":"65","author":"Kase","year":"2001","journal-title":"Biosci Biotechnol Biochem"},{"key":"10.1016\/j.bbr.2008.06.035_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0006-8993(98)01089-0","article-title":"Effect of selegiline on dopamine concentration in the striatum of a primate","volume":"815","author":"Kaseda","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2008.06.035_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(00)00745-7","article-title":"Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats","volume":"408","author":"Koga","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2008.06.035_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1476-5381.1994.tb16171.x","article-title":"Inhibition by KF17837 of adenosine A2A receptor-mediated modulation of striatal GABA and ACh release","volume":"113","author":"Kurokawa","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bbr.2008.06.035_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.21315","article-title":"Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201d time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)","volume":"63","author":"LeWitt","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2008.06.035_bib27","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/j.1460-2075.1991.tb07691.x","article-title":"The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor","volume":"10","author":"Libert","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/j.bbr.2008.06.035_bib28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF02245479","article-title":"Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets","volume":"109","author":"Loschmann","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2008.06.035_bib29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.107.121962","article-title":"Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition","volume":"323","author":"Mihara","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2008.06.035_bib30","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.108.051474","article-title":"Brain adenosine A2A receptor occupancy by a novel A1\/A2A receptor antagonist, ASP5854, in Rhesus monkeys: relationship to anticataleptic effect","author":"Mihara","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbr.2008.06.035_bib31","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.1523\/JNEUROSCI.20-20-07782.2000","article-title":"A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease","volume":"20","author":"Nash","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2008.06.035_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0006-8993(97)00584-2","article-title":"Increased dopamine turnover in the putamen after MPTP treatment in common marmosets","volume":"767","author":"Nomoto","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2008.06.035_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0304-3940(88)90095-X","article-title":"The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset","volume":"93","author":"Nomoto","year":"1988","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2008.06.035_bib34","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0091-3057(97)00552-2","article-title":"Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets","volume":"59","author":"Nomoto","year":"1998","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bbr.2008.06.035_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10639","article-title":"Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs","volume":"54","author":"Perry","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2008.06.035_bib36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1471-4159.2004.02887.x","article-title":"Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum","volume":"92","author":"Rodrigues","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2008.06.035_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2006.07.017","article-title":"The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets","volume":"546","author":"Rose","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2008.06.035_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2116\/analsci.19.67","article-title":"In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography","volume":"19","author":"Saji","year":"2003","journal-title":"Anal Sci"},{"key":"10.1016\/j.bbr.2008.06.035_bib39","first-page":"125","article-title":"Effects of treatment with trihexyphenidyl on cognitive function in early Parkinson's disease","volume":"33","author":"Schelosky","year":"1991","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.bbr.2008.06.035_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0303-2647(00)00135-0","article-title":"The cortico-basal ganglia-thalamocortical circuit with synaptic plasticity. II. Mechanism of synergistic modulation of thalamic activity via the direct and indirect pathways through the basal ganglia","volume":"59","author":"Silkis","year":"2001","journal-title":"Bio Systems"},{"key":"10.1016\/j.bbr.2008.06.035_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02252961","article-title":"Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist","volume":"9","author":"Starr","year":"1995","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bbr.2008.06.035_bib42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0014-2999(88)90322-6","article-title":"The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset","volume":"156","author":"Temlett","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2008.06.035_bib43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","article-title":"Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment","volume":"83","author":"Thanvi","year":"2007","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.bbr.2008.06.035_bib44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0303-8467(95)00011-8","article-title":"Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease","volume":"97","author":"van Kempen","year":"1995","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.bbr.2008.06.035_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(03)00337-9","article-title":"Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats","volume":"346","author":"Villanueva-Toledo","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2008.06.035_bib46","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2008.06.035_bib47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/0306-4522(87)90178-3","article-title":"An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset","volume":"23","author":"Waters","year":"1987","journal-title":"Neuroscience"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432808003495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432808003495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T09:58:24Z","timestamp":1557655104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432808003495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0166432808003495"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2008.06.035","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}